Agilent (AG8) Price & Analysis
AG8 Stock Chart & Stats
- Day’s Range
- CHF 143.72 - CHF 144.16
- 52-Week Range
- CHF 117.56 - CHF 150.55
- Previous Close
- CHF 150.09
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- CHF 40.62B
- Enterprise Value
- CHF 41.35B
- Total Cash (Recent Filing)
- CHF 1.76B
- Total Debt (Recent Filing)
- CHF 3.95B
- Price to Earnings (P/E)
- 34.4
- Beta
- 0.91
- Next Earnings
- Nov 23, 2026
- EPS Estimate
- 1.42
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.49%
Bulls Say, Bears Say
Bulls Say
Recurring Installed-base Revenue
Agilent’s instruments create an installed base that supports repeat purchases of consumables, maintenance, services and software. This recurring pull-through can deepen customer relationships, raise switching costs and make revenue more resilient than reliance on one-time equipment sales alone.
Raised Growth And Earnings Outlook
Raised full-year revenue and EPS guidance indicates that management sees demand and execution supporting continued expansion. The outlook also calls for more than 100 basis points of operating-margin growth excluding refunds, providing a constructive foundation for earnings over the next several quarters.
Strong Cash Generation
High free-cash-flow conversion gives Agilent meaningful capacity to fund research, product development, capital spending and shareholder returns. Strong cash generation also provides balance-sheet optionality, helping the company invest through market cycles without depending entirely on external financing.
Bears Say
Gross-margin Compression
The sharp decline in gross margin raises questions about the durability of profitability and the company’s ability to preserve pricing power. If mix, pricing or cost pressures persist, lower gross profit per dollar of revenue could constrain operating leverage and reduce earnings upside.
Higher Debt Reduces Flexibility
Higher debt increases fixed financial commitments and reduces flexibility if operating conditions weaken. Although leverage remains moderate, additional borrowing can limit the funds available for acquisitions, innovation or shareholder returns and makes disciplined capital allocation more important.
Operating Cash-flow Conversion Drag
Operating cash flow consistently trailing accounting earnings suggests working-capital or timing effects that can make cash realization uneven. Even with strong free cash flow overall, weaker conversion may create quarter-to-quarter volatility and reduce confidence that reported earnings translate smoothly into available cash.
Agilent News
AG8 FAQ
What was Agilent’s price range in the past 12 months?
What is Agilent’s market cap?
When is Agilent’s upcoming earnings report date?
How were Agilent’s earnings last quarter?
Is Agilent overvalued?
Does Agilent pay dividends?
What is Agilent’s EPS estimate?
How many shares outstanding does Agilent have?
What happened to Agilent’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Agilent?
What is the TipRanks Smart Score and how is it calculated?
Agilent Stock Smart Score
Company Description
Agilent
Agilent Technologies, Inc. delivers specialized, application-focused technologies and services to the global life sciences, diagnostics, and applied chemistry industries. Its Life Sciences and Applied Markets segment provides a comprehensive portfolio of analytical instrumentation. This includes liquid chromatography (LC) and gas chromatography (GC) systems, often integrated with mass spectrometry (MS) for advanced analysis (LC-MS, GC-MS). They also offer inductively coupled plasma mass spectrometry (ICP-MS), atomic absorption (AA), microwave plasma-atomic emission spectrometry (MP-AES), and inductively coupled plasma optical emission spectrometry (ICP-OES) instruments, alongside Raman spectroscopy for material characterization. Beyond spectroscopy, the segment supplies cell analysis solutions such as plate-based assays, flow cytometers, real-time cell analyzers, imaging systems, and microplate readers. Complementing these are various laboratory software, information management platforms, data analytics tools, automated and robotic lab systems, dissolution testing equipment, vacuum technology, and general measurement solutions. The Diagnostics and Genomics division offers cutting-edge tools for genetic and diagnostic research. These encompass arrays designed for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, and gene expression analysis. This segment also provides target enrichment solutions for next-generation sequencing, along with software for genetic data management and interpretation. Furthermore, it synthesizes custom oligonucleotides. Other significant offerings include immunohistochemistry (IHC), in situ hybridization (ISH), hematoxylin and eosin (H&E) staining, and specialized staining solutions. The division also supplies consumables and software essential for quality control analysis of nucleic acid samples, as well as reagents for turbidimetry and flow cytometry applications. A key area of development for this segment is liquid-based pharmacodiagnostics. Agilent CrossLab, the third segment, focuses on providing essential laboratory consumables and services. Its product range features GC and LC columns, products for sample preparation, custom chemical formulations, and various supplies for laboratory instruments. Complementary services include expert support for startup, ongoing operations, training, compliance, Software-as-a-Service (SaaS) offerings, asset management, and professional consultation. The company's products reach customers through a diverse sales network, including direct sales teams, distributors, resellers, manufacturer's representatives, and its e-commerce platforms. Agilent Technologies, Inc. was established in 1999 and maintains its corporate headquarters in Santa Clara, California.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Padraig McDonnell
- Employees
- 18,200
- Website
- www.agilent.com
- Address
- 5301 Stevens Creek Boulevard, Santa Clara, CA, 95051, US
Agilent (AG8) Earnings & Revenues
AG8 Company Deck
AG8 Earnings Call
Earnings Call SentimentPositive
The call conveyed strong operational and financial momentum: solid top-line beats, meaningful margin expansion (noting some benefit from one-time tariff refunds), raised full-year guidance, robust cash generation, continued product and China momentum, and visible benefits from the Ignite transformation. Lowlights were largely timing, one-time refund effects, regional softness in pockets (Europe, parts of C&E) and near-term variability related to CDMO ramp timing and macro/cost pressures. On balance the positives substantially outweighed the negatives.
View all CH:AG8 earnings summariesAG8 Net sales Breakdown
- 39.23% Life Sciences and Diagnostics Markets
- 41.85% Agilent CrossLab
- 18.91% Applied Markets
AG8 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 0 | 8 |
| Technical Analysis | 3 | 0 | 7 |
| Moving Averages | 5 | 0 | 1 |